Jennifer Wilson
Psychiatric/Mental Health · Yakima, WANPI 1972109254
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (36.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. E.r. Squibb & Sons, L.L.C. accounts for 88.4% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $20,886, more than ten times the $142 reported in 2021. Among psychiatric/mental health clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $170.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$20K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$675
- Teva Pharmaceuticals USA, Inc.$569
- Otsuka America Pharmaceutical, Inc.$413
- Alkermes, Inc.$316
- Neurocrine Biosciences, Inc.$220
- plus $472 from 7 others
What the payments were for
- Consulting fees$3,56116%
- Speaking & faculty fees$8,25136%
- Travel & lodging$6,25927%
- Food & beverage$4,74821%
- Education$1321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 57 | $20,285 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $675 |
| Teva Pharmaceuticals USA, Inc. | 17 | $569 |
| Otsuka America Pharmaceutical, Inc. | 26 | $413 |
| Alkermes, Inc. | 4 | $316 |
| Neurocrine Biosciences, Inc. | 5 | $220 |
| Johnson & Johnson | 2 | $177 |
| Axsome Therapeutics, Inc. | 2 | $143 |
| Janssen Scientific Affairs, LLC | 1 | $53 |
| Sunovion Pharmaceuticals Inc. | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| GSK | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COBENFY$15,936
- LYBALVI$502
- ARISTADA$480
- CAPLYTA$467
- INVEGA SUSTENNA$159
- INVEGA TRINZA$159
- INVEGA$159
- RISPERDAL$159
- INGREZZA$138
- ARISTADA INITIO$120
- REXULTI$119
- UZEDY$117
- Austedo XR$105
How this compares
$22,951 in reported general payments places this provider in the 95th percentile of 931 psychiatric/mental health providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 21 | $74,121 |
| AuvelityDextromethorphan Hbr/Bupropion | 47 | $38,223 |
| Abilify MaintenaAripiprazole | 12 | $37,467 |
| Risperdal ConstaRisperidone Microspheres | 13 | $15,958 |
| BelsomraSuvorexant | 31 | $13,809 |
| Quetiapine Fumarate | 375 | $9,585 |
| Paliperidone ErPaliperidone | 43 | $9,523 |
| Chlorpromazine Hcl | 24 | $5,811 |
| Clozapine | 70 | $5,378 |
| Divalproex Sodium ErDivalproex Sodium | 135 | $4,997 |
| Risperidone | 244 | $4,266 |
| Clonidine | 26 | $3,558 |
| Olanzapine OdtOlanzapine | 64 | $3,426 |
| Trazodone Hcl | 175 | $2,155 |
| Fluphenazine Hcl | 20 | $2,106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $177 | $90,07934 claims |
| Axsome Therapeutics, Inc.Auvelity | $143 | $38,22347 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $413 | $37,46712 claims |
| Lilly USA, LLCOlanzapine | $14 | $1,988110 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 931 psychiatric/mental health providers in Washington.
Other psychiatric/mental health in Yakima
- Ka ChanYakima$5K
- Angela CombsRichland$121K
- Ashley McGinnisAuburn$26K
- Courtney YantPuyallup$26K
- Dawn MasonSpokane$25K
- Kojo SarfoEllensburg$20K
- Brendan RoeVancouver$18K
- Jenna VoKent$18K
- Kelly BlissSeattle$18K
- Agnes MarambaKent$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.